Home About LOVAZA Guidelines Pharmacist Corner Patient Resources Professional Resources Prescribing Information
For Healthcare Professionals
About LOVAZA
E-MAIL SIGN UP

Stay informed. Sign up for our periodic E-mail.

Indication, Usage and Important Safety Information: LOVAZA™ (omega-3-acid ethyl esters) is indicated as an adjunct to diet to reduce very high (≥500 mg/dL) triglyceride (TG) levels in adult patients.

In individuals with hypertriglyceridemia (HTG), address excess body weight and alcohol intake before initiating any drug therapy. Diet and exercise can be important ancillary measures. Look for and treat diseases contributory to hyperlipidemia, such as hypothyroidism or diabetes mellitus. Certain treatments (e.g., estrogen therapy, thiazide diuretics and beta blockers) are sometimes associated with very significant rises in serum triglyceride (TG) levels. Discontinuation of the specific agent may obviate the need for specific drug therapy for HTG.

Consider lipid-regulating agent use only when reasonable attempts have been made to obtain satisfactory results with non-drug methods. Advise patients that lipid-regulating agent use does not reduce the importance of adhering to diet. (See PRECAUTIONS section of full prescribing information.)

In patients with very high TG levels the effect of LOVAZA on the risk of pancreatitis has not been evaluated, nor has its effect on cardiovascular mortality and morbidity been determined.

  1. LOVAZA is contraindicated in patients who exhibit hypersensitivity to any component of this medication.
  2. Before instituting LOVAZA therapy, it should be confirmed that TG levels are consistently abnormal.
  3. LOVAZA should be used with caution in patients with known sensitivity or allergy to fish.
  4. The patient’s TG, LDL-C and ALT levels should be monitored periodically during LOVAZA therapy. In some patients, LOVAZA increased LDL-C. LOVAZA therapy should be withdrawn in patients who do not have an adequate response after 2 months of treatment.
  5. Some studies with omega-3-acids demonstrated prolongation of bleeding time, which did not exceed normal limits and did not produce clinically significant bleeding episodes. Patients receiving treatment with both LOVAZA and anticoagulants should be monitored periodically.
  6. There are no adequate and well-controlled studies in pregnant women. Use LOVAZA during pregnancy only if the potential benefit justifies the potential risk to the fetus; and use with caution when administering LOVAZA to breastfeeding women.
  7. LOVAZA was well-tolerated in controlled studies. The most common adverse events reported were: eructation, infection, flu syndrome, dyspepsia, rash, taste perversion, and back pain.
  8. Please see full prescribing information.

Why patients benefit from LOVAZA™

In the management of very high triglycerides (≥500 mg/dL)...

LOVAZA has been clinically proven, along with diet, to provide dramatic triglyceride reductions and has demonstrated an excellent safety profile and proven tolerability.* 1, 2

LOVAZA Is Proven.

With just four 1-gram capsules per day, LOVAZA powerfully reduced very high triglycerides (≥500 mg/dL) by 45%.†1, 2

†Treatment resulted in a median increase of 45% in LDL-C; treatment with LOVAZA led to an overall reduction of atherogenic cholesterol, as reflected by a 14% reduction in non-HDL-C.1, 3-5

LOVAZA has more than 10 years of European experience.2

LOVAZA Is Potent.

Each 1-gram LOVAZA capsule contains 465 mg of eicosapentaenoic acid (EPA) and 375 mg of docosahexaenoic acid—for dramatic triglyceride reductions.

LOVAZA Is Pure.

LOVAZA provides prescription-only purity through a patent protected‡ 5-step refinement process.2, 6

*Some studies with omega-3 acids demonstrated prolongation of bleeding time

  • The prolongation of bleeding time reported in these studies has not exceeded normal limits and did not produce significant bleeding episodes
  • Patients receiving treatment with both LOVAZA and anticoagulants should be monitored periodically